DEEP TRACK CAPITAL LP
Q4 2021 Form 13-F

GREENWICH, CONNECTICUT
CIK 0001856083 · CRD 312459 · SEC-registered investment adviser
$1.4B Reported Value Total

DEEP TRACK CAPITAL, LP reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $1,792,544,185, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
2 funds · $8.4B gross asset value
Hedge Fund: $8.4B
Source: Form ADV filed 2026-03-31
Reported value
$1.4B
Quarter over quarter
0.0%
Holdings
49
Top-10 concentration
42.7%

Key People

Form ADV owners & control persons
David Eric Kroin
MANAGING MEMBER
Nir Salman Messafi
CHIEF OPERATING AND FINANCIAL OFFICER / CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2021 13F record

Q4 2021 13F filing summary

Q4 2021 Form 13F portfolio summary
Period of report December 31, 2021
Filed February 14, 2022
Form 13F-HR
Reported value $1.4B
Positions 49
Change in reported value First reported quarter
Top-10 concentration 42.7%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
71 $6.1B
Q2 2026 13F
Filed Aug 14, 2026
66 $6.9B
Q1 2026 13F
Filed May 15, 2026
62 $6.1B
Q4 2025 13F
Filed Feb 13, 2026
53 $5.6B
Q3 2025 13F
Filed Nov 14, 2025
56 $3.6B
Q2 2025 13F
Filed Aug 14, 2025
65 $3.1B
Q1 2025 13F
Filed May 15, 2025
69 $3.1B
Q4 2024 13F
Filed Feb 14, 2025
61 $2.7B
Q3 2024 13F
Filed Nov 14, 2024
69 $3.2B
Q2 2024 13F
Filed Aug 14, 2024
67 $3.4B
Q1 2024 13F
Filed May 15, 2024
65 $3.5B
Q4 2023 13F
Filed Feb 14, 2024
57 $3.0B
Q3 2023 13F
Filed Nov 14, 2023
62 $2.6B
Q2 2023 13F
Filed Aug 14, 2023
53 $2.2B
Q1 2023 13F
Filed May 15, 2023
54 $2.4B
Q4 2022 13F
Filed Feb 14, 2023
57 $2.4B
Q3 2022 13F
Filed Nov 14, 2022
60 $2.2B
Q2 2022 13F
Filed Aug 12, 2022
49 $1.5B
Q1 2022 13F
Filed May 16, 2022
49 $1.6B
Q4 2021 13F
Filed Feb 14, 2022
49 $1.4B

Top 20 holdings · Q4 2021

Largest Q4 2021 13F positions by reported value
# Holding Reported value % of portfolio
1 KROS KEROS THERAPEUTICS INC $76.1M 5.37%
2 TVTX TRAVERE THERAPEUTICS INC $76.0M 5.37%
3 BCYC BICYCLE THERAPEUTICS PLC $67.0M 4.73%
4 ISEE IVERIC BIO INC $66.9M 4.72%
5 JAZZ JAZZ PHARMACEUTICALS PLC $63.7M 4.5%
6 GBT GLOBAL BLOOD THERAPEUTICS IN $58.5M 4.13%
7 BEAM BEAM THERAPEUTICS INC $55.8M 3.94%
8 CRNX CRINETICS PHARMACEUTICALS IN $54.0M 3.81%
9 RPTX REPARE THERAPEUTICS INC $44.3M 3.13%
10 MDGL MADRIGAL PHARMACEUTICALS INC $42.4M 2.99%
11 FDMT 4D MOLECULAR THERAPEUTICS IN $41.7M 2.94%
12 NVCR NOVOCURE LTD $41.3M 2.92%
13 IMVT IMMUNOVANT INC $40.7M 2.87%
14 KDNY CHINOOK THERAPEUTICS INC $39.5M 2.79%
15 KURA KURA ONCOLOGY INC $35.7M 2.52%
16 DICE DICE THERAPEUTICS INC $33.9M 2.4%
17 JNCE JOUNCE THERAPEUTICS INC $33.4M 2.36%
18 ESPR ESPERION THERAPEUTICS INC NE $28.2M 1.99%
19 DYN DYNE THERAPEUTICS INC $27.3M 1.92%
20 VRDN VIRIDIAN THERAPEUTICS INC $26.4M 1.87%

Values as reported on the Q4 2021 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings